Marstacimab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TFPI |
| Clinical data | |
| Trade names | Hympavzi |
| Other names | PF-06741086, marstacimab-hncq |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a624071 |
| License data |
|
| Routes of administration | Subcutaneous |
| Drug class | Tissue factor pathway inhibitor (TFPI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6304H9766N1678O2006S44 |
| Molar mass | 142569.85 g·mol−1 |
Marstacimab, sold under the brand name Hympavzi, is a monoclonal antibody medication used for the treatment of hemophilia A and hemophilia B.[3][6][4] It is a tissue factor pathway inhibitor antagonist.[6] It was developed by Pfizer.[7] Marstacimab is a new type of medication that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor.[6] This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated.[6] This is expected to reduce or prevent the frequency of bleeding episodes.[6]
The most common side effects include injection site reactions, headache, and itching (pruritis).[6]
Marstacimab was approved for medical use in the United States in October 2024,[6][8] and in the European Union in November 2024.[5] The US Food and Drug Administration considers it to be a first-in-class medication.[9]
- ^ "Hympavzi (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 19 February 2025. Retrieved 7 March 2025.
- ^ "Hympavzi marstacimab 150mg/mL solution for injection, prefilled pen (438990)". Therapeutic Goods Administration (TGA). 30 January 2025. Retrieved 7 March 2025.
- ^ a b "Hympavzi- marstacimab-hncq injection, solution". DailyMed. 5 November 2024. Retrieved 11 November 2024.
- ^ a b Cite error: The named reference
Hympavzi EPARwas invoked but never defined (see the help page). - ^ a b "Hympavzi PI". Union Register of medicinal products. 19 November 2024. Retrieved 21 November 2024.
- ^ a b c d e f g Cite error: The named reference
FDA PR 20241011was invoked but never defined (see the help page). - ^ "FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B". Pfizer (Press release). 9 December 2023. Retrieved 21 September 2024.
- ^ "Hympavzi". U.S. Food and Drug Administration. 11 October 2024. Retrieved 24 June 2025. This article incorporates text from this source, which is in the public domain.
- ^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.